Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × brolucizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Cyclophosphamide 2819 Cisplatin 2797 Carboplatin 2598 Radiotherapy 2391 Paclitaxel 2385 Gemcitabine 2241 pembrolizumab 2048 Docetaxel 1941 Bevacizumab 1897 Fluorouracil 1636 Capecitabine 1599 Oxaliplatin 1525 Dexamethasone 1405 Nivolumab 1336 Doxorubicin 1327 Rituximab 1308 Etoposide 1195 Magnetic Resonance Spectroscopy 1119 Irinotecan 1110 Leucovorin 1086 Cytarabine 1004 Drug Therapy 938 Pemetrexed 931 fludarabine 923 Vincristine 850 Prednisone 836 Lenalidomide 819 Cetuximab 807 Specimen Handling 802 Filgrastim 799

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡